Company-wide revenue
Reported revenue in 2021 ¥12.69B Reported revenue in 2025 ¥26.84B
- growth amount
- +¥14.15B
- growth annualized
- +20.6%
- growth total
- +111.5%
Japanese company profile · 2160
GNI Group Ltd.
In its FY2025 public filing, GNI Group Ltd. reports Pharmaceuticals, Medical Devices Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社ジーエヌアイグループ
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
GNI Group Ltd.'s largest reported business by revenue in FY2025 was Pharmaceuticals.
The business with the highest reported segment profit in FY2025 was Medical Devices Business.
FY2025 · fiscal year ended December 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Revenue from external customers | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Pharmaceuticals | ¥19.16B ↗ | 71.4% | −¥4B ↗ |
| Medical Devices Business | ¥7.68B ↗ | 28.6% | ¥533M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Pharmaceuticals
- 医薬品事業
- Medical Devices Business
- 医療機器事業
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Pharmaceuticals
- 医薬品事業
- Medical Devices Business
- 医療機器事業
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Reported Revenue from external customers by business over time
Reported Revenue from external customers by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Pharmaceuticals | ¥10.9B | ¥14.99B | ¥22.98B | ¥18.3B | ¥19.16B |
| Medical Devices Business | ¥1.8B | ¥2.43B | ¥3.03B | ¥5.31B | ¥7.68B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Pharmaceuticals
Reported revenue in 2021 ¥10.9B Reported revenue in 2025 ¥19.16B
- growth amount
- +¥8.26B
- growth total
- +75.8%
View original filing
Medical Devices Business
Reported revenue in 2021 ¥1.8B Reported revenue in 2025 ¥7.68B
- growth amount
- +¥5.89B
- growth annualized
- +43.8%
- growth total
- +327.9%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XV4B
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.